Use, misuse and abuse of androgens - The Endocrine Society of Australia consensus guidelines for androgen prescribing

被引:68
作者
Conway, AJ [1 ]
Handelsman, DJ [1 ]
Lording, DW [1 ]
Stuckey, B [1 ]
Zajac, JD [1 ]
机构
[1] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia
关键词
D O I
10.5694/j.1326-5377.2000.tb123913.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Androgen replacement therapy (ART) is usually lifo-long, and should only be started after androgen deficiency has been proven by hormone assays. The therapeutic goal is to maintain physiological testosterone levels. Testosterone rather than synthetic androgens should be used. Oral 17 alpha-alkylated androgens are hepatotoxic and should not be used for ART. There is no indication for androgen therapy in male infertility. Although androgen deficiency Is an uncommon cause of erectile dysfunction, all men presenting with erectile dysfunction should be evaluated for androgen deficiency. If androgen deficiency is confirmed, investigation for the underlying pathological cause is required. Contraindications to androgen therapy are prostate and breast cancer. Precautions include using lower starling doses for older men and induction of puberty. Intramuscular injections should be avoided in men with bleeding disorders. Androgen-sensitive epilepsy, migraine, sloop apnoea, polycythaemia or fluid overload need to be considered. Competitive athletes should be warned about the risks of disqualification. ART should be initiated with Intramuscular Injections of testosterone esters, 250 mg twice weekly. Maintenance requires tailoring treatment modality to thf: patient's convenience. Modalities currently available include testosterone Injections, Implants, or capsules. Choice depends on convenience, cost, availability and familiarity. There is no convincing evidence that, in the absence of proven androgen deficiency, androgen therapy is effective and safe for older men per se, In men with chronic non-gonadal disease, or For treatment of nonspecific symptoms. Until further evidence Is available, such treatment cannot be recommended.
引用
收藏
页码:220 / 224
页数:21
相关论文
共 24 条
  • [1] The relationship of natural androgens to coronary heart disease in males: A review
    Alexandersen, P
    Haarbo, J
    Christiansen, C
    [J]. ATHEROSCLEROSIS, 1996, 125 (01) : 1 - 13
  • [2] SUBSTITUTION THERAPY OF HYPOGONADAL MEN WITH TRANSDERMAL TESTOSTERONE OVER ONE YEAR
    BALSPRATSCH, M
    LANGER, K
    PLACE, VA
    NIESCHLAG, E
    [J]. ACTA ENDOCRINOLOGICA, 1988, 118 (01): : 7 - 13
  • [3] BarrettConnor E, 1996, PHARMACOLOGY, BIOLOGY, AND CLINICAL APPLICATIONS OF ANDROGENS, P215
  • [4] Behre H., 1997, ANDROLOGY MALE REPRO, P87
  • [5] BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
  • [6] BEHRE HM, 1990, TESTOSTERONE ACTION, P115
  • [7] The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
    Bhasin, S
    Storer, TW
    Berman, N
    Callegari, C
    Clevenger, B
    Phillips, J
    Bunnell, TJ
    Tricker, R
    Shirazi, A
    Casaburi, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) : 1 - 7
  • [8] WHICH TESTOSTERONE REPLACEMENT THERAPY
    CANTRILL, JA
    DEWIS, P
    LARGE, DM
    NEWMAN, M
    ANDERSON, DC
    [J]. CLINICAL ENDOCRINOLOGY, 1984, 21 (02) : 97 - 107
  • [9] RANDOMIZED CLINICAL-TRIAL OF TESTOSTERONE REPLACEMENT THERAPY IN HYPOGONADAL MEN
    CONWAY, AJ
    BOYLAN, LM
    HOWE, C
    ROSS, G
    HANDELSMAN, DJ
    [J]. INTERNATIONAL JOURNAL OF ANDROLOGY, 1988, 11 (04): : 247 - 264
  • [10] CUMMINGS DE, 1994, CLIN ANDROLOGY, P893